GlassScriptPhysician profile
Kenneth Burns
NPI 1962768580
$2,974.58
in general payments reported to CMS, 2019-2025
37 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $106 · 2021: $555 · 2022: $693 · 2023: $620 · 2024: $146 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $499.78 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.06 | 2019-2023 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $275.08 | 2019-2025 | Breztri, Imfinzi, Tezspire |
| Mallinckrodt Hospital Products INC. | $200.43 | 2021-2023 | Acthar |
| Grifols USA, LLC | $141.93 | 2020-2023 | Xembify |
| Gilead Sciences, INC. | $138.70 | 2021-2024 | Veklury |
| Mylan Specialty L.P. | $114.26 | 2019-2022 | |
| Intuitive Surgical, INC. | $99.63 | 2024 | |
| United Therapeutics Corporation | $95.03 | 2020-2023 | Tyvaso |
| Merck Sharp & Dohme LLC | $89.29 | 2019-2023 | Zerbaxa, Dificid, Recarbrio |
| Inogen, INC. | $75.82 | 2023-2024 | Inogen |
| Collegium Pharmaceutical, INC. | $75.28 | 2025 | Belbuca |
| Actelion Pharmaceuticals US, INC. | $75.09 | 2022-2023 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $60.92 | 2019-2023 | Dupixent |
| Advanced Respiratory, INC | $54.78 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $47.30 | 2025 | Yupelri |
| Philips North America LLC | $43.76 | 2021-2022 | |
| Hospira, INC. | $43.45 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.22 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $40.97 | 2019 | |
| Ani Pharmaceuticals, INC. | $36.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.87 | 2021-2023 | Glassia |
| Shionogi INC | $33.14 | 2021-2023 | Fetroja |
| Teva Pharmaceuticals USA, INC. | $31.57 | 2021-2022 | |
| Insmed, INC. | $29.28 | 2019-2023 | Arikayce |
| Genentech USA, INC. | $27.32 | 2019-2021 | |
| Pfizer INC. | $27.05 | 2019-2025 | |
| Astellas Pharma US INC | $22.62 | 2019 | |
| Tactile Systems Technology INC | $19.96 | 2022 | |
| Amgen INC. | $19.91 | 2022 | |
| Bio Products Laboratory USA, INC. | $18.17 | 2019 | |
| Lilly USA, LLC | $18.02 | 2025 | Mounjaro, Zepbound |
| Jazz Pharmaceuticals INC. | $17.10 | 2022 | |
| Mallinckrodt Enterprises LLC | $16.08 | 2019 | |
| Electromed, INC. | $12.98 | 2022 | |
| Boston Scientific Corporation | $12.70 | 2023 | Exalt Model D |
| Phadia US INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.